Astorg and Cinven-backed LGC Group, an international life sciences measurement and tools company, completed the acquisition of Kova International, a developer, manufacturer and marketer of in vitro diagnostic products for the global urinalysis market, from One Rock Capital Partners, a private equity firm. Financial terms were not disclosed. “We are excited to bring Kova’s established clinical urinalysis and toxicology quality controls into LGC Clinical Diagnostics. Kova and LGC Clinical Diagnostics are an excellent fit. Our focus on delivering confidence to clinical laboratories in test precision, accuracy, and conformance to international standards, perfectly aligns us with a common objective of Science for a Safer World,” Bharathi Anekella, LGC Clinical Diagnostics Executive Vice President & General Manager.